Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

It's one of many changes Bayer CEO Bill Anderson has made. Still, the company's stock price this year has struggled.

The JV will focus on discovering and developing new drugs for conditions including haemophilia, heart disease in infants and a form of blindness called Stargardt. Bayer is just the latest in a ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

Additionally, the ophthalmology drug Eylea™ saw an 8.6% increase in sales. However, these positive developments were offset by a 23% decline in sales of Xarelto, which is Bayer's blockbuster ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bayer (OTCPK:BAYZF) noted that the global trial of 474 patients also reached all secondary endpoints, including a measure related to the reductions in the severity of VMS, and added that the drug ...

Bayer AG reported positive results for elinzanetant ... The German company’s drug met all the goals of a late-stage study for the treatment of moderate to severe vasomotor symptoms, also known ...